The pharmacogenetic variable “reduced metabolism of quetiapine”, based on the analysis of the CYP3A4*22 allele, was associated with lower scores in the CGI-BP-M overall and depression subscales, thus positively impacting the likelihood of response. This evidence concerns the gene CYP3A4 and major depressive disorder.